CENTENNIAL, Colo., Dec. 7, 2010 /PRNewswire/ -- LABS Inc., the premier transplant reference and consultative laboratory in the country, today announced that Kevin M. Smith, Chief Operating Officer of the Colorado Institute for Drug, Device and Diagnostic Development (CID4), has joined the company's Board of Directors. Smith brings a wealth of experience running businesses in the biosciences industries.
In addition to his current role as COO of CID4, Smith was a member of the group that developed the original business plan and state grant proposal for the organization. He also sits on the boards of Sophono, Inc.; PeptiVir, Inc., and participates on the Centura Audit and Corporate Responsibility Management Committee.
Prior to CID4, Smith was Managing Director of Act Three Consulting, LLC, which provided consulting services to management teams and their advisors during times of dramatic change. Before founding Act Three, Smith spent nine years as President of Gambro, Inc., the US holding company for the publicly-traded, Swedish-based Gambro Group. The US operations of Gambro included the manufacture and distribution of cardiovascular, blood separation and renal dialysis products and the operation of US and international kidney dialysis centers. Before joining Gambro, Smith was an audit partner in the Denver and New York offices of Ernst & Young, where he specialized in entrepreneurial services and led the formation of E&Y's Denver Life Sciences Practice.
"We are honored to have Kevin join our Board of Directors at this critical time in LABS Inc.'s growth," said Elizabeth Hearty, Chief Executive Officer of LABS Inc. "His personal connection to the transplant community and his experience driving strategic growth initiatives for bioscience companies will be a valuable addition to our already accomplished Board."
"I welcome the chance to work with the LABS Inc. team to forward its mission and capitalize on opportunit
|SOURCE LABS Inc.|
Copyright©2010 PR Newswire.
All rights reserved